Literature DB >> 27101756

Response to: 'Comment on Central retinal vein occlusion: modifying current treatment protocols'.

M Ashraf1, A A R Souka1, R P Singh2,3.   

Abstract

Entities:  

Year:  2016        PMID： 27101756      PMCID： PMC5129863          DOI： 10.1038/eye.2016.84

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  8 in total

1.  Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial.

Authors:  Jeffrey S Heier; Peter A Campochiaro; Linda Yau; Zhengrong Li; Namrata Saroj; Roman G Rubio; Phillip Lai
Journal:  Ophthalmology       Date:  2012-02-01       Impact factor: 12.079

2.  Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.

Authors:  Maximilian Pfau; Heidi Fassnacht-Riederle; Matthias D Becker; Nicole Graf; Stephan Michels
Journal:  Ophthalmic Res       Date:  2015-09-29       Impact factor: 2.892

3.  Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab.

Authors:  T D Papakostas; L Lim; T van Zyl; J B Miller; B S Modjtahedi; C M Andreoli; D Wu; L H Young; I K Kim; D G Vavvas; D D Esmaili; D Husain; D Eliott; L A Kim
Journal:  Eye (Lond)       Date:  2015-10-09       Impact factor: 3.775

4.  The effect of switching ranibizumab to aflibercept in refractory cases of macular edema secondary to ischemic central vein occlusion.

Authors:  L Lehmann-Clarke; A Dirani; I Mantel; A Ambresin
Journal:  Klin Monbl Augenheilkd       Date:  2015-04-22       Impact factor: 0.700

5.  Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study.

Authors:  Peter A Campochiaro; Charles C Wykoff; Michael Singer; Robert Johnson; Dennis Marcus; Linda Yau; Gary Sternberg
Journal:  Ophthalmology       Date:  2014-07-21       Impact factor: 12.079

6.  Scatter Photocoagulation Does Not Reduce Macular Edema or Treatment Burden in Patients with Retinal Vein Occlusion: The RELATE Trial.

Authors:  Peter A Campochiaro; Gulnar Hafiz; Tahreem A Mir; Adrienne W Scott; Sharon Solomon; Ingrid Zimmer-Galler; Akrit Sodhi; Elia Duh; Howard Ying; Adam Wenick; Syed Mahmood Shah; Diana V Do; Quan D Nguyen; Saleema Kherani; Raafay Sophie
Journal:  Ophthalmology       Date:  2015-05-09       Impact factor: 12.079

7.  Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year results of a prospective clinical study.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  J Ocul Pharmacol Ther       Date:  2014-10-14       Impact factor: 2.671

8.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration.

Authors:  Daniel F Martin; Maureen G Maguire; Gui-shuang Ying; Juan E Grunwald; Stuart L Fine; Glenn J Jaffe
Journal:  N Engl J Med       Date:  2011-04-28       Impact factor: 91.245
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.